Exon Skipping in a Dysf-Missense Mutant Mouse Model

Published on Dec 7, 2018in Molecular therapy. Nucleic acids7.032
· DOI :10.1016/J.OMTN.2018.08.013
Jakub Malcher1
Estimated H-index: 1
(French Institute of Health and Medical Research),
Leonie Victoria Heidt1
Estimated H-index: 1
(Charité)
+ 8 AuthorsVerena Schöwel5
Estimated H-index: 5
(MDC: Max Delbrück Center for Molecular Medicine)
Sources
Abstract
Limb girdle muscular dystrophy 2B (LGMD2B) is without treatment and caused by mutations in the dysferlin gene (DYSF). One-third is missense mutations leading to dysferlin aggregation and amyloid formation, in addition to defects in sarcolemmal repair and progressive muscle wasting. Dysferlin-null mouse models do not allow study of the consequences of missense mutations. We generated a new mouse model (MMex38) carrying a missense mutation in exon 38 in analogy to a clinically relevant human DYSF variant (DYSF p.Leu1341Pro). The targeted mutation induces all characteristics of missense mutant dysferlinopathy, including a progressive dystrophic pattern, amyloid formation, and defects in membrane repair. We chose U7 small nuclear RNA (snRNA)-based splice switching to demonstrate a possible exon-skipping strategy in this new animal model. We show that Dysf exons 37 and 38 can successfully be skipped in vivo. Overall, the MMex38 mouse model provides an ideal tool for preclinical development of treatment strategies for dysferlinopathy.
📖 Papers frequently viewed together
13 Citations
2 Citations
11 Authors (Katrin Wenzel, ..., Simone Spuler)
41 Citations
References52
Newest
#1Sara F. Henriques (Université Paris-Saclay)H-Index: 3
#2Cécile Patissier (Université Paris-Saclay)H-Index: 1
Last. Isabelle Richard (Université Paris-Saclay)H-Index: 22
view all 7 authors...
Sarcoglycanopathies are rare autosomic limb girdle muscular dystrophies caused by mutations in one of the genes coding for sarcoglycan (α, β, δ, and γ-sarcoglycans). Sarcoglycans form a complex, which is an important part of the dystrophin-associated glycoprotein complex that protects sarcolemma against muscle contraction-induced damages. Absence of one of the sarcoglycan at the plasma membrane induces the disappearance of the whole complex and perturbs muscle fiber membrane integrity. We previo...
7 CitationsSource
#1Valerie Robin (French Institute of Health and Medical Research)H-Index: 1
#2Graziella Griffith (French Institute of Health and Medical Research)H-Index: 8
Last. Aurélie Goyenvalle (French Institute of Health and Medical Research)H-Index: 12
view all 6 authors...
Spinal muscular atrophy (SMA) is a recessive disease caused by mutations in the SMN1 gene, which encodes the protein survival motor neuron (SMN), whose absence dramatically affects the survival of motor neurons. In humans, the severity of the disease is lessened by the presence of a gene copy, SMN2. SMN2 differs from SMN1 by a C-to-T transition in exon 7, which modifies pre-mRNA splicing and prevents successful SMN synthesis. Splice-switching approaches using antisense oligonucleotides (AONs) ha...
15 CitationsSource
#1Aurélie Goyenvalle (French Institute of Health and Medical Research)H-Index: 12
#2Christian J. Leumann (University of Bern)H-Index: 44
Last. Luis Garcia (French Institute of Health and Medical Research)H-Index: 28
view all 3 authors...
Oligonucleotide therapeutics hold great promise for the treatment of various diseases and the antisense field is constantly gaining interest due to the development of more potent and nuclease resistant chemistries. Despite a rather low success rate with only three antisense drugs being clinically approved, the frontiers of AON therapeutic applications have increased over the past three decades and continue to expand thanks to a steady increase in understanding the mechanisms of action of these m...
20 CitationsSource
#2Gabriella Dias Florencio (French Institute of Health and Medical Research)H-Index: 2
Last. Rachid BenchaouirH-Index: 6
view all 6 authors...
Recombinant adeno-associated viruses (rAAV) are largely used for gene transfer in research, preclinical developments, and clinical trials. Their broad in vivo biodistribution and long-term efficacy in postmitotic tissues make them good candidates for numerous gene transfer applications. Upstream processes able to produce large amounts of rAAV were developed, particularly those using baculovirus expression vector system. In parallel, downstream processes present a large panel of purification meth...
10 CitationsSource
#1Florian Barthélémy (French Institute of Health and Medical Research)H-Index: 8
#2Cédric M. Blouin (Curie Institute)H-Index: 14
Last. Marc BartoliH-Index: 30
view all 14 authors...
Dysferlinopathies are a family of disabling muscular dystrophies with LGMD2B and Miyoshi myopathy as the main phenotypes. They are associated with molecular defects in DYSF, which encodes dysferlin, a key player in sarcolemmal homeostasis. Previous investigations have suggested that exon skipping may be a promising therapy for a subset of patients with dysferlinopathies. Such an approach aims to rescue functional proteins when targeting modular proteins and specific tissues. We sought to evaluat...
15 CitationsSource
#1Aurélie Goyenvalle (French Institute of Health and Medical Research)H-Index: 12
#2Graziella Griffith (French Institute of Health and Medical Research)H-Index: 8
Last. Luis Garcia (French Institute of Health and Medical Research)H-Index: 28
view all 18 authors...
Antisense oligonucleotides (AONs) hold promise for therapeutic correction of many genetic diseases via exon skipping, and the first AON-based drugs have entered clinical trials for neuromuscular disorders1, 2. However, despite advances in AON chemistry and design, systemic use of AONs is limited because of poor tissue uptake, and recent clinical reports confirm that sufficient therapeutic efficacy has not yet been achieved. Here we present a new class of AONs made of tricyclo-DNA (tcDNA), which ...
185 CitationsSource
#1Gabriella Dias Florencio (French Institute of Health and Medical Research)H-Index: 2
#2Guillaume Précigout (French Institute of Health and Medical Research)H-Index: 3
Last. Rachid Benchaouir (French Institute of Health and Medical Research)H-Index: 4
view all 6 authors...
Recombinant adeno-associated viruses (rAAV) are promising candidates for gene therapy approaches. The last two decades were particularly fruitful in terms of processes applied in the production and purification of this type of gene transfer vectors. This rapid technological evolution led to better yields and higher levels of vector purity. Recently, some reports showed that rAAV produced by transient tri-transfection method in adherent human embryonic kidney 293 cells can be harvested directly f...
14 CitationsSource
#1Xiang-Dong Fu (UCSD: University of California, San Diego)H-Index: 95
#2Manuel Ares (UCSC: University of California, Santa Cruz)H-Index: 70
RNA-binding proteins (RBPs) influence alternative splicing in a highly context-sensitive and combinatorial manner, and it is therefore difficult to predict their actions on the basis of genomic sequence. However, recent progress in understanding alternative splicing, particularly using global approaches, has revealed new sets of rules for deciphering these patterns. This Review outlines the function of RBPs at different levels and describes the emerging rules of alternative splicing.
550 CitationsSource
#1Neville E. SanjanaH-Index: 32
#2Ophir ShalemH-Index: 20
Last. Feng ZhangH-Index: 155
view all 3 authors...
Genome-wide, targeted loss-of-function pooled screens using the CRISPR (clustered regularly interspaced short palindrome repeats)–associated nuclease Cas9 in human and mouse cells provide an alternative screening system to RNA interference (RNAi) and have been used to reveal new mechanisms in diverse biological models1-4. Previously, we used a Genome-scale CRISPR Knock-Out (GeCKO) library to identify loss-of-function mutations conferring vemurafenib resistance in a melanoma model1. However, init...
2,450 CitationsSource
#1Paul Porensky (OSU: Ohio State University)H-Index: 6
#2Arthur H.M. BurghesH-Index: 71
Abstract Spinal muscular atrophy (SMA) is an autosomal recessive disease affecting ∼1 in 10,000 live births. The most striking component is the loss of α-motor neurons in the ventral horn of the spinal cord, resulting in progressive paralysis and eventually premature death. There is no current treatment paradigm other than supportive care, though the past 15 years has seen a striking advancement in understanding of both SMA genetics and molecular mechanisms. A variety of disease-modifying interv...
64 CitationsSource
Cited By7
Newest
#1Helena Escobar (Charité)
#1Helena Escobar (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 1
Last. Simone Spuler (Charité)H-Index: 34
view all 10 authors...
Skeletal muscle can regenerate from muscle stem cells and their myogenic precursor cell progeny, myoblasts. However, precise gene editing in human muscle stem cells for autologous cell replacement therapies of untreatable genetic muscle diseases has not yet been reported. Loss-of-function mutations in SGCA, encoding α-sarcoglycan, cause limb-girdle muscular dystrophy 2D/R3, an early onset, severe and rapidly progressive form of muscular dystrophy affecting equally girls and boys. Patients suffer...
1 CitationsSource
#1Minchul Kim (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 3
#1Minchul KimH-Index: 13
Last. Carmen BirchmeierH-Index: 89
view all 8 authors...
Syncytial skeletal muscle cells contain hundreds of nuclei in a shared cytoplasm. We investigated nuclear heterogeneity and transcriptional dynamics in the uninjured and regenerating muscle using single-nucleus RNA-sequencing (snRNAseq) of isolated nuclei from muscle fibers. This revealed distinct nuclear subtypes unrelated to fiber type diversity, previously unknown subtypes as well as the expected ones at the neuromuscular and myotendinous junctions. In fibers of the Mdx dystrophy mouse model,...
19 CitationsSource
#1Esther Fernández-Simón (Autonomous University of Barcelona)H-Index: 5
#2Cinta Lleixà (Autonomous University of Barcelona)H-Index: 5
Last. Noemi de Luna (Autonomous University of Barcelona)H-Index: 15
view all 7 authors...
Background Dysferlinopathies are a group of muscle disorders causing muscle weakness and absence or low levels of dysferlin, a type-II transmembrane protein and the causative gene of these dystrophies. Dysferlin is implicated in vesicle fusion, trafficking, and membrane repair. Muscle biopsy of patients with dysferlinopathy is characterized by the presence of inflammatory infiltrates. Studies in the muscle of both human and mouse models of dysferlinopathy suggest dysferlin deficient muscle plays...
Source
#1Rachel Thompson (Children's Hospital of Eastern Ontario)H-Index: 15
#2Sally Spendiff (Children's Hospital of Eastern Ontario)H-Index: 11
Last. Hanns LochmüllerH-Index: 95
view all 8 authors...
Summary Advances in DNA sequencing technologies have resulted in a near doubling, in under 10 years, of the number of causal genes identified for inherited neuromuscular disorders. However, around half of patients, whether children or adults, do not receive a molecular diagnosis after initial diagnostic workup. Massively parallel technologies targeting RNA, proteins, and metabolites are being increasingly used to diagnose these unsolved cases. The use of these technologies to delineate pathways,...
12 CitationsSource
#1Jennifer E. Morgan (NIHR: National Institute for Health Research)H-Index: 7
#1Jennifer Morgan (NIHR: National Institute for Health Research)H-Index: 2
Last. Terence A. Partridge (NIHR: National Institute for Health Research)H-Index: 70
view all 2 authors...
ABSTRACT Skeletal muscle fibres are multinucleated cells that contain postmitotic nuclei (i.e. they are no longer able to divide) and perform muscle contraction. They are formed by fusion of muscle precursor cells, and grow into elongating myofibres by the addition of further precursor cells, called satellite cells, which are also responsible for regeneration following injury. Skeletal muscle regeneration occurs in most muscular dystrophies in response to necrosis of muscle fibres. However, the ...
20 CitationsSource
#1Jaeho Hwang (U of A: University of Alberta)H-Index: 1
#2Toshifumi Yokota (U of A: University of Alberta)H-Index: 34
Muscular dystrophy is a group of genetic disorders characterised by degeneration of muscles. Different forms of muscular dystrophy can show varying phenotypes with a wide range of age, severity and location of muscle deterioration. Many palliative care options are available for muscular dystrophy patients, but no curative treatment is available. Exon-skipping therapy aims to induce skipping of exons with disease-causing mutations and/or nearby exons to restore the reading frame, which results in...
11 CitationsSource